The MHRA has obtained court orders freezing more than £200,000 linked to Alluvi Healthcare as part of an ongoing investigation into illicit weight-loss injections, including products labelled as retatrutide. The BBC has reported on four raids over nine months and thousands of seized doses. Here is what the case reveals — and why anyone considering buying unapproved injections outside a regulated pharmacy needs to understand what "illicit" actually means.
More than £200,000 held across three bank accounts has been frozen as part of an ongoing Medicines and Healthcare products Regulatory Agency (MHRA) investigation into illicit weight-loss injections.
According to BBC reporting, the three accounts are linked to an investigation involving products carrying Alluvi Healthcare branding. The freezing orders were granted at Northampton Magistrates’ Court following an application by the MHRA under the Proceeds of Crime Act.
The amounts reported were £131,985.66 in one account, £56,816.90 in an account belonging to Ecommerce Nutri Collectiv Limited, and £11,706 in a third account. The orders allow the money to remain frozen while the investigation continues.
The BBC reports that over the past nine months the MHRA has carried out four raids in which thousands of doses of Alluvi-branded weight-loss products were uncovered. Products seized during the wider investigation have included injections labelled as tirzepatide and retatrutide.
The MHRA has said the investigation concerns what it believes to be an organised network involved in the production, distribution and sale of illicit injections.
It is important to be precise about the legal position. These are ongoing investigations and enforcement proceedings. A freezing order is not a criminal conviction, and allegations have not been proven merely because funds have been frozen or products seized.
What Does “Illicit” Mean in This Case?
Weight-loss medicines sold in the UK are subject to strict controls over how they are manufactured, prescribed and supplied.
In this investigation, the BBC reports that the seized injections were not manufactured in licensed laboratories. As a result, their ingredients, sterility, dosage and quality cannot be guaranteed.
That is an important distinction for consumers.
Professional packaging, a branded box, a pre-filled injection pen or a convincing website does not demonstrate that a medicine has been manufactured to pharmaceutical standards or authorised by the MHRA.
The MHRA has repeatedly warned that medicines obtained outside legitimate supply chains may not contain what buyers expect and may be contaminated, incorrectly dosed or otherwise unsafe. During an earlier Northampton raid in October 2025, officers seized raw ingredients, manufacturing equipment, thousands of empty pens and more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch.
Why Retatrutide Is Particularly Significant
Tirzepatide and retatrutide have very different regulatory positions in the UK.
Tirzepatide is an authorised medicine. It is sold as Mounjaro and can be prescribed for eligible patients through regulated healthcare providers and pharmacies.
Retatrutide is not currently an authorised UK medicine.
Retatrutide, developed by Eli Lilly, is an investigational obesity treatment that activates the GIP, GLP-1 and glucagon receptors. It is continuing through clinical development and has not yet received UK marketing authorisation.
The MHRA states that retatrutide has not been approved for UK use and warns that products claiming to contain retatrutide which are sold outside authorised clinical trials are likely to be illegal and potentially dangerous.
For UK patients, this means an authorised clinical trial is currently the regulated route through which retatrutide may be administered. There is no licensed retatrutide pen available from UK pharmacies.
That does not mean nothing is known about retatrutide. Clinical trials have produced substantial data about the medicine. What it means is that regulators have not yet completed the process required to authorise it for routine clinical use in the UK.
You can read more about the medicine, its clinical trials and its UK status in our Retatrutide UK guide.
The “Own-Brand” Dimension
One of the more unusual aspects of the MHRA investigation is the branding.
Andy Morling, head of the MHRA’s Criminal Enforcement Unit, told the BBC that the investigation was the first time he had encountered suspected operators creating their own brand rather than producing counterfeit versions of existing pharmaceutical brands.
That is an important difference.
Traditional counterfeit medicines attempt to imitate an established product such as Mounjaro or Wegovy. Buyers may believe they are purchasing the genuine pharmaceutical product.
An own-brand injection creates a different problem. A professionally designed box or branded pen can give the appearance of a pharmaceutical medicine even though there is no authorised reference product from that brand against which a consumer can verify it.
The BBC reports that Alluvi-branded products had been promoted on websites and social-media platforms including Telegram, Instagram and TikTok.
Branding alone is therefore not evidence that a medicine is authorised, pharmaceutical-grade or produced in a licensed facility.
A Wider Investigation, Not a Single Raid
The latest financial action is part of a much larger investigation.
In October 2025, the MHRA said officers had dismantled an illicit weight-loss medicine manufacturing facility in Northampton. They recovered raw chemical ingredients, manufacturing equipment, tens of thousands of empty pens and more than 2,000 unlicensed retatrutide and tirzepatide pens.
Then, in May 2026, officers raided a property near Northampton and recovered around 12,000 doses of unlicensed weight-loss medicines, including products labelled as retatrutide and tirzepatide as well as other peptide products. Two men were arrested on suspicion of offences under the Human Medicines Regulations 2012. The MHRA said at the time that enquiries were continuing.
The BBC now reports that four raids have taken place over approximately nine months as part of the wider investigation.
Mounjaro vs Unapproved Tirzepatide and Retatrutide Products
It is worth separating the medicine itself from whatever name appears on an unregulated product.
Licensed Mounjaro contains tirzepatide, but that does not mean every injection labelled “tirzepatide” is Mounjaro or has been manufactured by Eli Lilly.
A licensed medicine supplied through a regulated UK pharmacy comes through an authorised manufacturing and distribution chain and is supplied following an appropriate prescription and clinical assessment.
A product purchased from an unregulated website, social-media account or messaging group does not provide those same assurances simply because its label says “tirzepatide”.
The distinction is even clearer with retatrutide because there is currently no authorised retatrutide medicine available to buy from a UK pharmacy at all.
If you are considering licensed tirzepatide treatment, our Mounjaro UK guide explains how regulated UK access works.
What This Means for UK Patients
The Alluvi investigation highlights a growing problem created by enormous public interest in new weight-loss medicines.
People searching online may encounter professional websites, branded injection pens and products presented using pharmaceutical terminology. None of those things establish that the product has been authorised or manufactured under the regulatory standards applied to licensed medicines.
For tirzepatide, there is a regulated UK route through licensed Mounjaro supplied following a prescription.
For retatrutide, there is currently no authorised UK retail product.
The MHRA investigation remains ongoing, and the freezing of funds should not be interpreted as a finding of guilt.
What the case does demonstrate is the scale of the regulator’s current enforcement activity around unlicensed weight-loss injections. The MHRA says it is using raids, online disruption and asset-recovery powers to target suspected illegal medicines supply networks.
Anyone concerned about an injection they have already purchased or used should speak to a doctor, pharmacist or other appropriate healthcare professional.
Frequently Asked Questions
Is retatrutide approved in the UK?
No. Retatrutide remains an investigational medicine and does not currently have UK marketing authorisation.
The MHRA says products claiming to contain retatrutide that are sold outside authorised clinical trials are likely to be illegal and potentially dangerous.
What does freezing a bank account under the Proceeds of Crime Act mean?
An account-freezing order prevents money from being moved while investigators examine whether funds may represent recoverable property connected with unlawful activity.
It is an investigative and asset-preservation measure. It is not a criminal conviction.
In this case, the BBC reports that the orders allow the funds in the three accounts to remain frozen for 12 months.
How can I check whether a weight-loss medicine supplier is legitimate?
Prescription weight-loss medicines should be prescribed appropriately and supplied through regulated healthcare and pharmacy channels.
The MHRA maintains a register of authorised online sellers of medicines, and pharmacy registration can also be checked with the General Pharmaceutical Council.
Be particularly cautious about prescription or investigational injections offered through social media, messaging apps or websites that do not provide a verifiable regulated pharmacy route.
Does this investigation affect licensed Mounjaro or Wegovy?
No.
The investigation concerns unlicensed products outside the regulated medicines supply chain. Licensed Mounjaro and Wegovy supplied appropriately through registered UK pharmacies are separate from the products involved in this investigation.
What should I do if I have used an injection bought from an unregulated source?
If you are concerned about something you have injected, particularly if you feel unwell, contact an appropriate healthcare professional.
Suspected adverse reactions can also be reported through the MHRA Yellow Card scheme. The MHRA specifically encourages people who believe they are experiencing medicine side effects to speak to a doctor, pharmacist or nurse and submit a Yellow Card report.
This article is for information purposes only and does not constitute medical advice. Always consult an appropriately qualified healthcare professional about treatment decisions.
